Aphria (NYSE:APHA) PT Set at $8.30 by Jefferies Financial Group

Aphria (NYSE:APHA) has been given a $8.30 price target by equities researchers at Jefferies Financial Group in a report released on Tuesday, TipRanks reports. The firm currently has a “buy” rating on the stock. Jefferies Financial Group’s price objective indicates a potential upside of 67.34% from the stock’s previous close. Jefferies Financial Group also issued estimates for Aphria’s Q3 2020 earnings at $0.00 EPS and FY2022 earnings at $0.39 EPS.

APHA has been the subject of several other research reports. CIBC reiterated a “sell” rating and issued a $6.50 price objective on shares of Aphria in a research note on Wednesday. ValuEngine upgraded shares of Aphria from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Zacks Investment Research cut shares of Aphria from a “buy” rating to a “hold” rating in a research note on Tuesday, October 8th. Finally, Pi Financial set a $9.00 price objective on shares of Aphria and gave the stock a “buy” rating in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the stock. Aphria currently has an average rating of “Buy” and a consensus price target of $11.57.

Aphria stock traded up $0.10 during midday trading on Tuesday, hitting $4.96. The company’s stock had a trading volume of 2,889,431 shares, compared to its average volume of 4,841,672. Aphria has a 1-year low of $3.75 and a 1-year high of $15.86. The company has a 50-day moving average price of $5.90 and a two-hundred day moving average price of $6.84. The company has a market cap of $1.10 billion, a price-to-earnings ratio of -45.09 and a beta of 2.85.

Aphria (NYSE:APHA) last issued its quarterly earnings data on Tuesday, October 15th. The company reported $0.07 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.10. The business had revenue of $126.10 million during the quarter, compared to analyst estimates of $131.15 million. The company’s revenue for the quarter was up 848.1% on a year-over-year basis. As a group, equities research analysts forecast that Aphria will post 0.01 earnings per share for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in the business. Capital Investment Advisory Services LLC grew its holdings in shares of Aphria by 2,233.3% during the 2nd quarter. Capital Investment Advisory Services LLC now owns 7,000 shares of the company’s stock valued at $43,000 after purchasing an additional 6,700 shares during the last quarter. Exane Derivatives grew its holdings in shares of Aphria by 333.7% during the 2nd quarter. Exane Derivatives now owns 103,130 shares of the company’s stock valued at $723,000 after purchasing an additional 79,350 shares during the last quarter. CIBC Asset Management Inc grew its holdings in shares of Aphria by 7.8% during the 2nd quarter. CIBC Asset Management Inc now owns 125,725 shares of the company’s stock valued at $884,000 after purchasing an additional 9,108 shares during the last quarter. AE Wealth Management LLC bought a new stake in shares of Aphria during the 2nd quarter valued at approximately $153,000. Finally, Swiss National Bank grew its holdings in shares of Aphria by 8.0% during the 2nd quarter. Swiss National Bank now owns 445,400 shares of the company’s stock valued at $3,132,000 after purchasing an additional 33,000 shares during the last quarter. 10.94% of the stock is currently owned by hedge funds and other institutional investors.

About Aphria

Aphria Inc produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc is headquartered in Leamington, Canada.

Further Reading: What is operating income?

Analyst Recommendations for Aphria (NYSE:APHA)

Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.